GLMD - ガルメド・ファ―マシュ―ティカルズ （Galmed Pharmaceuticals Ltd.）

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS ) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) climbed 162% to $0.4909 after the company announced it acquired Amerigen 7. Cryptyde, Inc. (NASDAQ: TYDE ) gained 108% to $0.4022. Geron Corporation (NASDAQ: GERN ) shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint. Shift Technologies, Inc. (NASDAQ: SFT ) rose 49% to $0.2350. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) jumped 42.4% to $0.4132. The company earlier reported in 13G filing Sabby Volatility Warrant Master Fund held 11% stake in Neptune Wellness Solutions. Reunion Neuroscience Inc. (NASDAQ: REUN ) gained 27.8% to $1.33. Armata Pharmaceuticals, Inc. (NASDAQ: ARMP ) surged 25% to $ 1.3799.

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24 Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is actively looking for partnering opportunities to continue Aramchol''s clinical development. TEL AVIV, Israel , Jan. 4, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD ) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases reported today full results from the Open-Label Part of the ARMOR study corroborating effects of Aramchol across all efficacy parameters.

Gainers Horizon Global Corporation (NYSE: HZN ) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. Jasper Therapeutics, Inc. (NASDAQ: JSPR ) gained 257% to $1.70 after the company announced clinical data from a Phase I/II trial of briquilimab as a conditioning treatment in sickle cell disease and beta thalassemia. ReShape Lifesciences Inc. (NASDAQ: RSLS ) shares jumped 142.3% to $16.34. Reshape Lifesciences recently announced a 1-for-50 reverse stock split. Lucira Health, Inc. (NASDAQ: LHDX ) surged 68% to $0.1875 after the company announced it submitted an Emergency Use Authorization application to the FDA for OTC use of its COVID-19 & Flu test. Swvl Holdings Corp. (NASDAQ: SWVL ) shares gained 43% to $0.1958 after the company reported commencement of strategic review process. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) jumped 41% to $0.5678. Vivos Therapeutics recently posted a Q3 loss of $0.26 per share. EpicQuest Education Group International Limited (NASDAQ: EEIQ ) gained 40.1% to $3.0962.

Galmed Pharmaceuticals (GLMD) received a letter from The Nasdaq, notifying the company that it is eligible for an additional 180 calendar day period, or until June 12, 2023.This…

TEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a letter from The Nasdaq Stock…

https://www.investing.com/news/pro/maxim-group-downgrades-galmed-pharmaceuticals-to-hold-432SI-2866585

https://www.investing.com/news/pro/canaccord-genuity-downgrades-galmed-pharmaceuticals-to-hold-432SI-2866300

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Rope in stocks: Mustang Bio, Inc. (NASDAQ:MBIO 8.78%), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD -9.52%) appeared first on Stocks Equity .

https://www.investing.com/news/pro/cantor-fitzgerald-downgrades-galmed-pharmaceuticals-to-neutral-432SI-2863917

Galmed Pharmaceuticals (NASDAQ: GLMD ) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Galmed Pharmaceuticals beat estimated earnings by 37.5%, reporting … Full story available on Benzinga.com

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment with Aramchol resulted in statistically significant improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone, the gold standard … Full story available on Benzinga.com

Galmed Pharmaceuticals Ltd. saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 23,200 shares, a drop of 27.3% from…

Galmed Pharmaceuticals (GLMD) shares fell 8.41% after Raymond James Analyst Steven Seedhouse downgraded the ratings of the biotechnology company to Market Perform from Outperform without…

Galmed Pharmaceuticals (NASDAQ: GLMD ) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Galmed Pharmaceuticals beat estimated earnings by 25.0%, reporting … Full story available on Benzinga.com

TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022….